Live-attenuated Listeria Monocytogenes Encoding Egfrviii-mesothelin Vaccine Jnj-64041757
Live-attenuated Listeria Monocytogenes Encoding Egfrviii-mesothelin Vaccine Jnj-64041757 Uses, Dosage, Side Effects, Food Interaction and all others data.
Live-attenuated Listeria Monocytogenes Encoding Egfrviii-mesothelin Vaccine Jnj-64041757 is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).
| Trade Name | Live-attenuated Listeria Monocytogenes Encoding Egfrviii-mesothelin Vaccine Jnj-64041757 |
| Generic | Pemlimogene merolisbac |
| Pemlimogene merolisbac Other Names | Ladd listeria monocytogenes jnj-64041757, Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757, Pemlimogene merolisbac, Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein (actan100), 5 tandem copies of a 21 amino acid fr |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Live-attenuated Listeria Monocytogenes Encoding Egfrviii-mesothelin Vaccine Jnj-64041757
